A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome
Identifieur interne : 000D72 ( Istex/Corpus ); précédent : 000D71; suivant : 000D73A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome
Auteurs : Roger Kurlan ; Giovanna Crespi ; Barbara Coffey ; Kirsten Mueller-Vahl ; Stephen Koval ; Glen WunderlichSource :
- Movement Disorders [ 0885-3185 ] ; 2012-05.
English descriptors
Abstract
Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.
Url:
DOI: 10.1002/mds.24919
Links to Exploration step
ISTEX:563328031B9EB7FF732D960D9842281AACFC3197Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome</title><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><affiliation><mods:affiliation>Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Atlantic Neuroscience Institute, Overlook Hospital, 99 Beauvoir Ave., Summit, NJ 07902, USA</mods:affiliation></affiliation></author><author><name sortKey="Crespi, Giovanna" sort="Crespi, Giovanna" uniqKey="Crespi G" first="Giovanna" last="Crespi">Giovanna Crespi</name><affiliation><mods:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</mods:affiliation></affiliation></author><author><name sortKey="Coffey, Barbara" sort="Coffey, Barbara" uniqKey="Coffey B" first="Barbara" last="Coffey">Barbara Coffey</name><affiliation><mods:affiliation>Department of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Mueller Ahl, Kirsten" sort="Mueller Ahl, Kirsten" uniqKey="Mueller Ahl K" first="Kirsten" last="Mueller-Vahl">Kirsten Mueller-Vahl</name><affiliation><mods:affiliation>Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany</mods:affiliation></affiliation></author><author><name sortKey="Koval, Stephen" sort="Koval, Stephen" uniqKey="Koval S" first="Stephen" last="Koval">Stephen Koval</name><affiliation><mods:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</mods:affiliation></affiliation></author><author><name sortKey="Wunderlich, Glen" sort="Wunderlich, Glen" uniqKey="Wunderlich G" first="Glen" last="Wunderlich">Glen Wunderlich</name><affiliation><mods:affiliation>Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:563328031B9EB7FF732D960D9842281AACFC3197</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/mds.24919</idno><idno type="url">https://api-v5.istex.fr/document/563328031B9EB7FF732D960D9842281AACFC3197/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D72</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000D72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome</title><author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name><affiliation><mods:affiliation>Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Atlantic Neuroscience Institute, Overlook Hospital, 99 Beauvoir Ave., Summit, NJ 07902, USA</mods:affiliation></affiliation></author><author><name sortKey="Crespi, Giovanna" sort="Crespi, Giovanna" uniqKey="Crespi G" first="Giovanna" last="Crespi">Giovanna Crespi</name><affiliation><mods:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</mods:affiliation></affiliation></author><author><name sortKey="Coffey, Barbara" sort="Coffey, Barbara" uniqKey="Coffey B" first="Barbara" last="Coffey">Barbara Coffey</name><affiliation><mods:affiliation>Department of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Mueller Ahl, Kirsten" sort="Mueller Ahl, Kirsten" uniqKey="Mueller Ahl K" first="Kirsten" last="Mueller-Vahl">Kirsten Mueller-Vahl</name><affiliation><mods:affiliation>Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany</mods:affiliation></affiliation></author><author><name sortKey="Koval, Stephen" sort="Koval, Stephen" uniqKey="Koval S" first="Stephen" last="Koval">Stephen Koval</name><affiliation><mods:affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</mods:affiliation></affiliation></author><author><name sortKey="Wunderlich, Glen" sort="Wunderlich, Glen" uniqKey="Wunderlich G" first="Glen" last="Wunderlich">Glen Wunderlich</name><affiliation><mods:affiliation>Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-05">2012-05</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="775">775</biblScope><biblScope unit="page" to="778">778</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">563328031B9EB7FF732D960D9842281AACFC3197</idno><idno type="DOI">10.1002/mds.24919</idno><idno type="ArticleID">MDS24919</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Tourette's syndrome</term><term>dopamine agonist</term><term>pramipexole</term><term>tics</term><term>treatment, clinical trial</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Roger Kurlan MD</name><affiliations><json:string>Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, USA</json:string><json:string>Atlantic Neuroscience Institute, Overlook Hospital, 99 Beauvoir Ave., Summit, NJ 07902, USA</json:string></affiliations></json:item><json:item><name>Giovanna Crespi PharmD</name><affiliations><json:string>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</json:string></affiliations></json:item><json:item><name>Barbara Coffey MD, MS</name><affiliations><json:string>Department of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York, USA</json:string><json:string>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA</json:string></affiliations></json:item><json:item><name>Kirsten Mueller‐Vahl MD</name><affiliations><json:string>Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany</json:string></affiliations></json:item><json:item><name>Stephen Koval MS</name><affiliations><json:string>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</json:string></affiliations></json:item><json:item><name>Glen Wunderlich PhD</name><affiliations><json:string>Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Tourette's syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pramipexole</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment, clinical trial</value></json:item></subject><articleId><json:string>MDS24919</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>5.156</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>119</abstractCharCount><pdfWordCount>5418</pdfWordCount><pdfCharCount>36791</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>13</abstractWordCount></qualityIndicators><title>A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome</title><corporate><json:item><name>on behalf of the Pramipexole for TS Trial Investigators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>27</volume><issue>6</issue><pages><first>775</first><last>778</last><total>3</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Brief Report</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1002/mds.24919</json:string></doi><id>563328031B9EB7FF732D960D9842281AACFC3197</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/563328031B9EB7FF732D960D9842281AACFC3197/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/563328031B9EB7FF732D960D9842281AACFC3197/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/563328031B9EB7FF732D960D9842281AACFC3197/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2012 Movement Disorder Society</p></availability><date>2012</date></publicationStmt><notesStmt><note type="content">*Funding agencies: The study was sponsored by Boehringer‐Ingelheim.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><note type="content">*See Appendix for names of Pramipexole for TS Trial Investigators</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome</title><author><orgName>on behalf of the Pramipexole for TS Trial Investigators</orgName></author><author xml:id="author-1"><persName><forename type="first">Roger</forename><surname>Kurlan</surname></persName><roleName type="degree">MD</roleName><affiliation>Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, USA</affiliation><affiliation>Atlantic Neuroscience Institute, Overlook Hospital, 99 Beauvoir Ave., Summit, NJ 07902, USA</affiliation></author><author xml:id="author-2"><persName><forename type="first">Giovanna</forename><surname>Crespi</surname></persName><roleName type="degree">PharmD</roleName><affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</affiliation></author><author xml:id="author-3"><persName><forename type="first">Barbara</forename><surname>Coffey</surname></persName><roleName type="degree">MD, MS</roleName><affiliation>Department of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York, USA</affiliation><affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA</affiliation></author><author xml:id="author-4"><persName><forename type="first">Kirsten</forename><surname>Mueller‐Vahl</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany</affiliation></author><author xml:id="author-5"><persName><forename type="first">Stephen</forename><surname>Koval</surname></persName><roleName type="degree">MS</roleName><affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</affiliation></author><author xml:id="author-6"><persName><forename type="first">Glen</forename><surname>Wunderlich</surname></persName><roleName type="degree">PhD</roleName><affiliation>Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-05"></date><biblScope unit="volume">27</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="775">775</biblScope><biblScope unit="page" to="778">778</biblScope></imprint></monogr><idno type="istex">563328031B9EB7FF732D960D9842281AACFC3197</idno><idno type="DOI">10.1002/mds.24919</idno><idno type="ArticleID">MDS24919</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.</p></abstract><abstract><p>There was a multicenter randomized, placebo‐controlled, double‐blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome.</p></abstract><abstract><p>There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole (−7.16) and placebo (−7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent‐ and investigator‐scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo.</p></abstract><abstract><p>There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder. © 2012 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Tourette's syndrome</term></item><item><term>tics</term></item><item><term>pramipexole</term></item><item><term>dopamine agonist</term></item><item><term>treatment, clinical trial</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-06-15">Received</change><change when="2012-01-01">Registration</change><change when="2012-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/563328031B9EB7FF732D960D9842281AACFC3197/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/mds.v27.6</doi><numberingGroup><numbering type="journalVolume" number="27">27</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2012-05">May 2012</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="220" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.24919</doi><idGroup><id type="unit" value="MDS24919"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2012 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2011-06-15"></event><event type="manuscriptRevised" date="2011-12-09"></event><event type="manuscriptAccepted" date="2012-01-01"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.5 mode:FullText" date="2012-05-30"></event><event type="publishedOnlineEarlyUnpaginated" date="2012-03-07"></event><event type="firstOnline" date="2012-03-07"></event><event type="publishedOnlineFinalForm" date="2012-05-30"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-24"></event></eventGroup><numberingGroup><numbering type="pageFirst">775</numbering><numbering type="pageLast">778</numbering></numberingGroup><correspondenceTo>Atlantic Neuroscience Institute, Overlook Hospital, 99 Beauvoir Ave., Summit, NJ 07902, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS24919.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="20"></count><count type="wordTotal" number="3456"></count></countGroup><titleGroup><title type="main" xml:lang="en">A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome<link href="#fn2"></link><link href="#fn3"></link><link href="#fn4"></link><link href="#fn1"></link></title><title type="short" xml:lang="en">Clinical Trial of Pramipexole for TS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Roger</givenNames><familyName>Kurlan</familyName><degrees>MD</degrees></personName><contactDetails><email>roger.kurlan@atlantichealth.org</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Giovanna</givenNames><familyName>Crespi</familyName><degrees>PharmD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>Barbara</givenNames><familyName>Coffey</familyName><degrees>MD, MS</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Kirsten</givenNames><familyName>Mueller‐Vahl</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Stephen</givenNames><familyName>Koval</familyName><degrees>MS</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Glen</givenNames><familyName>Wunderlich</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><groupName>on behalf of the Pramipexole for TS Trial Investigators</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="DE" type="organization"><unparsedAffiliation>Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="CA" type="organization"><unparsedAffiliation>Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Tourette's syndrome</keyword><keyword xml:id="kwd2">tics</keyword><keyword xml:id="kwd3">pramipexole</keyword><keyword xml:id="kwd4">dopamine agonist</keyword><keyword xml:id="kwd5">treatment, clinical trial</keyword></keywordGroup><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds24919:MDS_24919_sm_SuppInfo"></mediaResource><caption>Supporting Information</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background:</title><p>Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>There was a multicenter randomized, placebo‐controlled, double‐blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole (−7.16) and placebo (−7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent‐ and investigator‐scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo.</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder. © 2012 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn2"><p><b>Funding agencies</b>: The study was sponsored by Boehringer‐Ingelheim.</p></note><note xml:id="fn3"><p><b>Relevant conflicts of interest/financial disclosures</b>: Nothing to report.</p></note><note xml:id="fn4"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note><note xml:id="fn1"><p>See Appendix for names of Pramipexole for TS Trial Investigators</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Clinical Trial of Pramipexole for TS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome</title></titleInfo><name type="personal"><namePart type="given">Roger</namePart><namePart type="family">Kurlan</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, USA</affiliation><affiliation>Atlantic Neuroscience Institute, Overlook Hospital, 99 Beauvoir Ave., Summit, NJ 07902, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giovanna</namePart><namePart type="family">Crespi</namePart><namePart type="termsOfAddress">PharmD</namePart><affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Barbara</namePart><namePart type="family">Coffey</namePart><namePart type="termsOfAddress">MD, MS</namePart><affiliation>Department of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York, USA</affiliation><affiliation>Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kirsten</namePart><namePart type="family">Mueller‐Vahl</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephen</namePart><namePart type="family">Koval</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glen</namePart><namePart type="family">Wunderlich</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>on behalf of the Pramipexole for TS Trial Investigators</namePart><description>Atlantic Neuroscience Institute, Overlook Hospital, Summit, New Jersey, USABoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USADepartment of Child and Adolescent Psychiatry, New York University School of Medicine, New York, New York, USANathan Kline Institute for Psychiatric Research, Orangeburg, New York, USADepartment of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, GermanyBoehringer Ingelheim (Canada) Ltd., Burlington, Ontario, Canada</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2012-05</dateIssued><dateCaptured encoding="w3cdtf">2011-06-15</dateCaptured><dateValid encoding="w3cdtf">2012-01-01</dateValid><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">20</extent><extent unit="words">3456</extent></physicalDescription><abstract>Dopamine agonists could theoretically normalize the suspected central dopamine hypersensitivity in Tourette's syndrome.</abstract><abstract>There was a multicenter randomized, placebo‐controlled, double‐blind clinical trial of pramipexole given for 6 weeks in 63 children and adolescents with Tourette's syndrome.</abstract><abstract>There were no significant differences in the adjusted mean change in the Total Tic Score of the Yale Global Tic Severity Scale for patients treated with pramipexole (−7.16) and placebo (−7.17). There were no significant treatment effects on change from baseline in the Global Severity score of the Yale Scale and parent‐ and investigator‐scored Clinical Global Impression of Improvement. In patients with attention deficit hyperactivity disorder, there was improvement in DuPaul ADHD scale scores for patients receiving pramipexole compared with placebo.</abstract><abstract>There was no evidence that pramipexole has efficacy in suppressing tics. Pramipexole may decrease symptoms of associated attention deficit hyperactivity disorder. © 2012 Movement Disorder Society</abstract><note type="content">*Funding agencies: The study was sponsored by Boehringer‐Ingelheim.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><note type="content">*See Appendix for names of Pramipexole for TS Trial Investigators</note><subject lang="en"><genre>keywords</genre><topic>Tourette's syndrome</topic><topic>tics</topic><topic>pramipexole</topic><topic>dopamine agonist</topic><topic>treatment, clinical trial</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information - </note><subject><genre>article-category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>775</start><end>778</end><total>3</total></extent></part></relatedItem><identifier type="istex">563328031B9EB7FF732D960D9842281AACFC3197</identifier><identifier type="DOI">10.1002/mds.24919</identifier><identifier type="ArticleID">MDS24919</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2012 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:563328031B9EB7FF732D960D9842281AACFC3197
|texte= A multicenter randomized placebo‐controlled clinical trial of pramipexole for Tourette's syndrome
}}
| This area was generated with Dilib version V0.6.29. |  |